Immunotherapy plus chemo before surgery: a new hope for breast cancer?
NCT ID NCT06908668
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding an immunotherapy drug called adebrelimab to chemotherapy, with or without radiation, before surgery can help eliminate HER2-negative locally advanced breast cancer. About 170 women aged 18-70 will participate. The main goal is to see if the cancer completely disappears by the time of surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Adebrelimab (an immunotherapy drug) combined with chemotherapy (albumin-bound paclitaxel, epirubicin, cyclophosphamide) and optionally radiotherapy
What this could lead to
If successful, this approach could improve the chance of eliminating all cancer before surgery, potentially leading to better long-term outcomes for patients with this type of breast cancer.
What could go wrong
This is a Phase 2 trial with only 170 participants, so results are preliminary. The added treatments may cause more side effects, and it's unknown if the combination will work better than standard therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-NEGATIVE LOCALLY ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, China
Contact Phone: •••-•••-••••